MX2021004114A - Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. - Google Patents
Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.Info
- Publication number
- MX2021004114A MX2021004114A MX2021004114A MX2021004114A MX2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A
- Authority
- MX
- Mexico
- Prior art keywords
- staphylococcus aureus
- directed against
- antibodies directed
- against staphylococcus
- aureus leukotoxins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743501P | 2018-10-09 | 2018-10-09 | |
| PCT/US2019/055144 WO2020076790A1 (en) | 2018-10-09 | 2019-10-08 | Antibodies directed against staphylococcus aureus leukotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004114A true MX2021004114A (es) | 2021-07-16 |
Family
ID=68393067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004114A MX2021004114A (es) | 2018-10-09 | 2019-10-08 | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11059884B2 (https=) |
| EP (1) | EP3864040A1 (https=) |
| JP (1) | JP7459075B2 (https=) |
| CN (1) | CN113015745B (https=) |
| AU (1) | AU2019359207A1 (https=) |
| BR (1) | BR112021006704A2 (https=) |
| CA (1) | CA3115765A1 (https=) |
| MX (1) | MX2021004114A (https=) |
| TW (1) | TWI895248B (https=) |
| WO (1) | WO2020076790A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015010125A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| TWI895248B (zh) | 2018-10-09 | 2025-09-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| CN113811544A (zh) | 2019-03-13 | 2021-12-17 | 免疫医疗有限责任公司 | 减少定殖患者中的金黄色葡萄球菌感染 |
| CN113493510A (zh) * | 2021-07-07 | 2021-10-12 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 |
| CN113583119B (zh) * | 2021-07-07 | 2023-05-02 | 西北农林科技大学 | 抗金黄色葡萄球菌的纳米抗体Nb56、应用及试剂盒 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| CN104119438A (zh) | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| EP4015523A1 (en) | 2010-05-05 | 2022-06-22 | New York University | Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof |
| PT2673373T (pt) | 2011-02-08 | 2018-12-05 | Medimmune Llc | Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização |
| KR20210083389A (ko) | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| BR112015010125A2 (pt) | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
| RU2016119052A3 (en) * | 2013-10-17 | 2018-09-10 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody sequences |
| ES2869459T3 (es) | 2014-05-16 | 2021-10-25 | Medimmune Llc | Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| CN107873034A (zh) | 2015-04-17 | 2018-04-03 | 阿尔萨尼斯生物科学有限责任公司 | 抗金黄色葡萄球菌抗体组合制剂 |
| WO2017075188A2 (en) | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| TWI895248B (zh) | 2018-10-09 | 2025-09-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
-
2019
- 2019-10-08 TW TW108136342A patent/TWI895248B/zh active
- 2019-10-08 MX MX2021004114A patent/MX2021004114A/es unknown
- 2019-10-08 EP EP19795711.1A patent/EP3864040A1/en active Pending
- 2019-10-08 CN CN201980074188.5A patent/CN113015745B/zh active Active
- 2019-10-08 US US16/596,445 patent/US11059884B2/en active Active
- 2019-10-08 AU AU2019359207A patent/AU2019359207A1/en active Pending
- 2019-10-08 CA CA3115765A patent/CA3115765A1/en active Pending
- 2019-10-08 BR BR112021006704-3A patent/BR112021006704A2/pt unknown
- 2019-10-08 WO PCT/US2019/055144 patent/WO2020076790A1/en not_active Ceased
- 2019-10-08 JP JP2021519609A patent/JP7459075B2/ja active Active
-
2021
- 2021-06-07 US US17/340,622 patent/US11578119B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI895248B (zh) | 2025-09-01 |
| WO2020076790A1 (en) | 2020-04-16 |
| EP3864040A1 (en) | 2021-08-18 |
| BR112021006704A2 (pt) | 2021-08-10 |
| KR20210080411A (ko) | 2021-06-30 |
| CN113015745A (zh) | 2021-06-22 |
| US11578119B2 (en) | 2023-02-14 |
| AU2019359207A1 (en) | 2021-05-20 |
| JP2022512646A (ja) | 2022-02-07 |
| JP7459075B2 (ja) | 2024-04-01 |
| CN113015745B (zh) | 2025-02-11 |
| US20210363229A1 (en) | 2021-11-25 |
| US11059884B2 (en) | 2021-07-13 |
| CA3115765A1 (en) | 2020-04-16 |
| TW202028232A (zh) | 2020-08-01 |
| US20200109190A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004114A (es) | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| CR20200566A (es) | Anticuerpos anti-sirpa y metodos de utilización de los mismos | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| MX2021005394A (es) | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| PH12019500929A1 (en) | Anti il-33 antibodies and uses thereof | |
| WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| EP4556576A3 (en) | Methods to diagnose and treat acute respiratory infections | |
| MX2019010922A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| WO2016062722A8 (en) | Combination | |
| PH12022553106A1 (en) | Sars-cov-2-antibodies and methods of selecting and using the same | |
| EA201992546A1 (ru) | Средства на основе антител к cd33 | |
| MX2017011019A (es) | Prueba de susceptibilidad antimicrobiana e identificacion de bacterias. | |
| WO2018148486A8 (en) | Anti-factor d antibodies and uses thereof | |
| MY191346A (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
| TW201613575A (en) | Treatment of polybacterial infections | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| MX2021004173A (es) | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. | |
| PH12021550332A1 (en) | Anti-cd33 antibodies and methods of use thereof |